Get started
Author

Ursina Zürrer‐Härdi

Observed names: U. Zürrer, Ursina Zuerrer-Haerdi, Ursina Zuerrer-Hardi, Ursina Zürrer, Ursina Zürrer-Härdi, Zurrer-Härdi, U., Zürrer, Ursina, Zürrer-Härdi Ursina, Zürrer-Härdi, U., Zürrer-Härdi, Ursina
Observed institutions: University of Basel, University of Zurich, Triemli Hospital, Kantonsspital Winterthur, University Hospital Zurich, Kantonsspital Graubünden
ORCID: 0000-0002-6672-8104
Observed ORCID: 0000-0002-6672-8104
OpenAlex ID: A5008330682
Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State
2012 · Wenjun Guo, Zuzana Keckesova, et al. · Cell · 1,011
PDF
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
2020 · Sabine Schmid, Aurelius Omlin, et al. · JAMA Network Open · 118
PDF
IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity
2010 · Nicole M. Probst-Hensch, Julia H.B. Steiner, et al. · Clinical Cancer Research · 59
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer
2023 · Christoph Mamot, Andreas Wicki, et al. · Scientific Reports · 56
PDF
Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer
2010 · Jean-Philippe Theurillat, Birgit Dreier, et al. · Modern Pathology · 51
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy
2007 · Jean-Philippe Theurillat, Ursina Zürrer-Härdi, et al. · Cancer Immunology Immunotherapy · 49
PDF
Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores
2010 · Kristian Ikenberg, Florian R Fritzsche, et al. · BMC Cancer · 33
PDF
Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine
2014 · Katharina E. Hofer, Colette Degrandi, et al. · Clinical Toxicology · 30
PDF
Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort
2022 · Mahesh Sarki, Chang Ming, et al. · Cancers · 25
PDF
Distinct expression patterns of the immunogenic differentiation antigen NY‐BR‐1 in normal breast, testis and their malignant counterparts
2007 · Jean‐Philippe Theurillat, Ursina Zürrer‐Härdi, et al. · International Journal of Cancer · 20
Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort
2022 · Mahesh Sarki, Chang Ming, et al. · Journal of Personalized Medicine · 18
PDF
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
2019 · Michael Mark, Beat Thürlimann, et al. · Journal of bone oncology · 17
PDF
Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study
2021 · Sue Kim, Monica Aceti, et al. · JMIR Research Protocols · 16
PDF
Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes
2011 · Zsuzsanna Varga, Cathy B. Moelans, et al. · Breast Cancer Research and Treatment · 13
PDF
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)
2021 · Karin Ribi, Beat Thürlimann, et al. · BMC Cancer · 10
PDF
Acceptability and Usability of the Family Gene Toolkit for Swiss and Korean Families Harboring BRCA1/BRAC2 Pathogenic Variants: A Web-Based Platform for Cascade Genetic Testing
2023 · Vasiliki Baroutsou, Vu Duong, et al. · Cancers · 9
PDF
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study
2021 · Sandro T. Stoffel, Roger Von Moos, et al. · Swiss Medical Weekly · 9
PDF
A Requirement for p120-catenin in the metastasis of invasive ductal breast cancer
2020 · Sarah J. Kurley, Verena Tischler, et al. · Journal of Cell Science · 7
PDF
Navigating complex choices through legitimation: Narrative strategies in risk-reduction mastectomy decision-making among unaffected women with genetic risk for breast cancer in Switzerland
2024 · Maria Caiata-Zufferey, Reka Schweighoffer, et al. · SSM - Qualitative Research in Health · 4
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)
2025 · Marian Klose, Ilaria Colombo, et al. · Clinical Pharmacokinetics · 1
Abstract PS5-08-16: Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Controlled Trial
2026 · U. Zürrer, A. Müller, et al. · Clinical Cancer Research
Clinical Impact of Polygenic Risk Score Integration into CanRisk in Women with Familial Breast Cancer Risk and Negative Germline Testing: A Prospective Multicenter Study (PRoScreen)
2026 · Tobias Bethge, Riniker Salome, et al. · SSRN Electronic Journal
Health Behaviors and Cancer Diagnosis Among Individuals with Pathogenic Variants Associated with Hereditary Breast and Ovarian Cancer or Lynch Syndrome
2025 · Mahesh Sarki, Günther Fink, et al. · Journal of Personalized Medicine
PDF
2490P Identification of pathogenic germline variants by germline-focused tumour analysis in a European study of high-risk and advanced prostate cancer patients
2025 · R. Graffeo, M. Nerone, et al. · Annals of Oncology
Abstract PS5-06: Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)
2025 · Andreas Müller, Arnoud J Templeton, et al. · Clinical Cancer Research
Works count: 40
Citation count: 1,556
H-index: 13
I10-index: 15
Year
Topic
Type